| Date | Title |
|---|---|
|
05/13/20
|
Source
News of Calithera’s planned clinical trial evaluating candidate CB-280 in people with cystic fibrosis is highlighted by Cystic Fibrosis News Today.
|
|
10/18/19
|
Source
Calithera is highlighted by San Francisco Business Times among notable biotechs who raised funds in June of 2019.
|
|
10/01/19
|
Source
UroToday highlights the latest therapeutic advances in RCC, including the significance of the Phase 2 ENTRATA clinical study results evaluating telaglenastat in advanced RCC that were presented at ESMO 2019.
|
|
09/28/19
|
Source
OncLive highlights the Phase 2 ENTRATA study results presented at ESMO 2019, including perspective from study investigator Chung-Han Lee, MD, PhD.
|
|
09/28/19
|
Source
In this video interview with Oncology Tube, ENTRATA clinical study investigator Chung-Han Lee, MD, PhD, discusses the ENTRATA study results presented at ESMO 2019 and their implications for clinicians.
|
|
06/18/19
|
Source
Calithera’s positive ENTRATA Phase 2 study demonstrating the benefit of telaglenastat in combination with everolimus in treating RCC is discussed in this June 2019 OncLive article
|
|
06/17/19
|
Source
Industry news source SCRIP discusses data from the ENTRATA trial and its proof-of-concept implications for Calithera’s lead compound, telaglenastat.
|
Investors
In the Media
Investor & Media ContactStephanie Wong 1.650.870.1063 |